Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Hale

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Molecular Cancer Research : MCR|April 20, 2019
GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast CancerSamantha M Bevill, Jose F Olivares-Quintero, Noah Sciaky, et al.
The Journal of Clinical Investigation|November 20, 2012
Endothelial Kruppel-like factor 4 protects against atherothrombosis in miceGuangjin Zhou, Anne Hamik, Lalitha Nayak, et al.
Circulation|February 29, 2012
MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approachVictoria N Parikh, Richard C Jin, Sabrina Rabello, et al.
The Journal of Clinical Investigation|May 16, 2022
Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertensionThomas Bertero, Yu Lu, Sofia Annis, et al.
The Journal of Clinical Investigation|June 25, 2014
Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertensionThomas Bertero, Yu Lu, Sofia Annis, et al.
Cell Reports|November 14, 2015
Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 CircuitThomas Bertero, Katherine A Cottrill, Yu Lu, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Molecular Cancer Research : MCR|April 20, 2019
GSK2801, a BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast CancerSamantha M Bevill, Jose F Olivares-Quintero, Noah Sciaky, et al.
The Journal of Clinical Investigation|November 20, 2012
Endothelial Kruppel-like factor 4 protects against atherothrombosis in miceGuangjin Zhou, Anne Hamik, Lalitha Nayak, et al.
Circulation|February 29, 2012
MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approachVictoria N Parikh, Richard C Jin, Sabrina Rabello, et al.
The Journal of Clinical Investigation|May 16, 2022
Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertensionThomas Bertero, Yu Lu, Sofia Annis, et al.
The Journal of Clinical Investigation|June 25, 2014
Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertensionThomas Bertero, Yu Lu, Sofia Annis, et al.
Cell Reports|November 14, 2015
Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 CircuitThomas Bertero, Katherine A Cottrill, Yu Lu, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 4